A New and Innovative Method for CO2 Removal in Anesthetic Circuits
memsorb
1 other identifier
interventional
286
1 country
2
Brief Summary
The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2017
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 12, 2016
CompletedFirst Posted
Study publicly available on registry
January 9, 2017
CompletedStudy Start
First participant enrolled
March 20, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 10, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 24, 2024
CompletedResults Posted
Study results publicly available
February 23, 2026
CompletedFebruary 23, 2026
February 1, 2026
5.1 years
October 12, 2016
March 18, 2025
February 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
End-tidal CO2 Concentration (%)
The mean concentration of carbon dioxide during the expiratory cycle, measured as a percentage (%), measured over the course of the surgical procedure.
From the start to the end of the intra-operative period for each participant
Other Outcomes (1)
Fraction of Anaesthetic Agent (%)
From the start to the end of the intra-operative period for each participant
Study Arms (2)
Control
NO INTERVENTIONPatients receive standard care with a standard CO2 absorber and agree to include their data in the study.
memsorb
EXPERIMENTALPatients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
Interventions
Eligibility Criteria
You may qualify if:
- American Society of Anesthesiologists Physical Status Class I, II, III (low-medium risk patient)
- English-speaking patients
You may not qualify if:
- Self-reported as pregnant
- American Society of Anesthesiologists Physical Status Class IV (high risk patient)
- Patients scheduled for emergency surgery
- Documented respiratory disease, including COPD and severe asthma
- Documented elevated pressure in the brain (intra cranial pressure, ICP)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Queen Elizabeth II HSC, Halifax Infirmary Site
Halifax, Nova Scotia, B3H 3A7, Canada
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
Limitations and Caveats
Early termination in McGill branch due to limited ability to recruit.
Results Point of Contact
- Title
- Katy Schurman
- Organization
- DMF Medical Inc.
Study Officials
- PRINCIPAL INVESTIGATOR
Orlando Hung, MD
Nova Scotia Health Authority
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- LTE60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 12, 2016
First Posted
January 9, 2017
Study Start
March 20, 2017
Primary Completion
May 10, 2022
Study Completion
July 24, 2024
Last Updated
February 23, 2026
Results First Posted
February 23, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share